Evidence map›Paper›PMID 23478869›Full record

ArticlePediatrics2013

Evidence of small-fiber polyneuropathy in unexplained, juvenile-onset, widespread pain syndromes.

Anne Louise Oaklander, Max M Klein

Open access · bronzeAbstract readEvaluation Study
In one paragraph

Article in Pediatrics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Advances in diagnosis and management of distal sensory polyneuropathies.Journal of neurology, neurosurgery, and psychiatry · 2023
    Review
  8. Review
  9. Review
  10. Review
  11. The puzzle of fibromyalgia between central sensitization syndrome and small fiber neuropathy: a narrative review on neurophysiological and morphological evidence.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022
    Review
  12. Review
  13. Cutaneous manifestations of orthostatic intolerance syndromes.International journal of women's dermatology · 2021
    Article
  14. Article
  15. Article
  16. Article
  17. Acute monophasic erythromelalgia pain in five children diagnosed as small-fiber neuropathy.European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society · 2020
    Article
  18. Article
  19. Current Diagnosis and Treatment of Painful Small Fiber Neuropathy.Current neurology and neuroscience reports · 2019
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Anne Louise OaklanderDepartment of Neurology, Massachusetts General Hospital, 275 Charles St/Warren 310, Boston, MA 02114, USA. aoaklander@partners.org
Max M Klein
Harvard University · USMassachusetts General Hospital · US

Funding

Evaluation of Small-Fiber Polyneuropathy in YouthR01NS093653 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI OAKLANDER, ANNE LOUISE · 2015 to 2024
$7.2M
Pathophysiology and diagnosis of neurological pain syndromesK24NS059892 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI OAKLANDER, ANNE LOUISE · 2008 to 2012
$949k
NINDS NIH HHS K24 NS059892NINDS NIH HHS K24NS059892NINDS NIH HHS R01 NS093653
6 · The paper itself

Abstract

objectiveWe tested the hypothesis that acquired small-fiber polyneuropathy (SFPN), previously uncharacterized in children, contributes to unexplained pediatric widespread pain syndromes.

methodsForty-one consecutive patients evaluated for unexplained widespread pain beginning before age 21 had medical records comprehensively analyzed regarding objective diagnostic testing for SFPN (neurodiagnostic skin biopsy, nerve biopsy, and autonomic function testing), plus histories, symptoms, signs, other tests, and treatments. Healthy, demographically matched volunteers provided normal controls for SFPN tests.

resultsAge at illness onset averaged 12.3 ± 5.7 years; 73% among this poly-ethnic sample were female (P = .001). Sixty-eight percent were chronically disabled, and 68% had hospitalizations. Objective testing diagnosed definite SFPN in 59%, probable SFPN in 17%, and possible SFPN in 22%. Only 1 of 41 had entirely normal SFPN test results. Ninety-eight percent of patients had other somatic complaints consistent with SFPN dysautonomia (90% cardiovascular, 82% gastrointestinal, and 34% urologic), 83% reported chronic fatigue, and 63% had chronic headache. Neurologic examinations identified reduced sensation in 68% and vasomotor abnormalities in 55%, including 23% with erythromelalgia. Exhaustive investigations for SFPN causality identified only history of autoimmune illnesses in 33% and serologic markers of disordered immunity in 89%. Treatment with corticosteroids and/or intravenous immune globulin objectively and subjectively benefited 80% of patients (12/15).

conclusionsMore than half among a large series of patients with childhood-onset, unexplained chronic widespread pain met rigorous, multitest, diagnostic criteria for SFPN, which extends the age range of acquired SFPN into early childhood. Some cases appeared immune-mediated and improved with immunomodulatory therapies.

Indexed as

AdolescentAdrenal Cortex HormonesAdultAutoimmune DiseasesBiopsyCase-Control StudiesChildChild, PreschoolChronic PainElectromyographyFemaleHumansImmunoglobulins, IntravenousImmunologic FactorsMaleNerve FibersAdrenal Cortex HormonesImmunoglobulins, IntravenousImmunologic Factors

Identifiers

PMID23478869
PMCPMC4074641
OpenAlexW2014438197

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.